PANcreatic-DERived factor (PANDER, FAM3B) is a novel protein that is highly expressed within the endocrine pancreas and to a lesser degree in other tissues. Under glucose stimulation, PANDER is co-secreted with insulin from the b-cell. Despite prior creation and characterization of acute hepatic PANDER animal models, the physiologic function remains to be elucidated from pancreas-secreted PANDER. To determine this, in this study, a transgenic mouse exclusively overexpressing PANDER from the endocrine pancreas was generated. PANDER was selectively expressed by the pancreatic-duodenal homeobox-1 (PDX1) promoter. The PANDER transgenic (PANTG) mice were metabolically and proteomically characterized to evaluate effects on glucose homeostasis, insulin sensitivity, and lipid metabolism. Fasting glucose, insulin and C-peptide levels were elevated in the PANTG compared with matched WT mice. Younger PANTG mice also displayed glucose intolerance in the absence of peripheral insulin sensitivity. Hyperinsulinemic-euglycemic clamp studies revealed that hepatic glucose production and insulin resistance were significantly increased in the PANTG with no difference in either glucose infusion rate or rate of disappearance. Fasting glucagon, corticosterones, resistin and leptin levels were also similar between PANTG and WT. Stable isotope labeling of amino acids in cell culture revealed increased gluconeogenic and lipogenic proteomic profiles within the liver of the PANTG with phosphoenol-pyruvate carboxykinase demonstrating a 3.5-fold increase in expression. This was matched with increased hepatic triglyceride content and decreased p-AMPK and p-acetyl coenzyme A carboxylase-1 signaling in the PANTG. Overall, our findings support a role of pancreatic b-cell-secreted PANDER in the regulation of hepatic insulin and lipogenenic signaling with subsequent impact on overall glycemia.
Introduction
PANcreatic-DERived factor (PANDER, FAM3B) is a 235-amino acid protein preferentially secreted and expressed from pancreatic a and b cells, and to lower levels in the intestine and prostate (Zhu et al. 2002 , Cao et al. 2003 .
In contrast to earlier findings, other investigators have detected the presence of PANDER in stomach, muscle, liver, and brain tissues . The family with sequence similarity 3 (FAM3) was identified using a computational algorithm known as ostensible recognition of folds (ORF; Aurora & Rose 1998) . This search identifies protein sequences that may form a four-helix-bundle structure based on predicted secondary structure that is typically found in many cytokines. From ORF, the predicted structure of FAM3B (name was changed to PANDER in 2003) was determined to be a four-helix bundle. Despite this initial prediction, recent crystallographic studies of secreted PANDER have revealed that the true structure is a globular b-b-a fold, demonstrated by the presence of two antiparallel b sheets lined by three short helices packed to form a highly conserved water-filled cavity (Johansson et al. 2013) . This unique structure continues to be preserved for other members of the FAM3 group, and thereby potentially constitutes a new class of signaling molecules distinctly different from other known cytokines or hormones.
With regard to biological function, in vitro studies revealed the increased production of PANDER mRNA and protein under glucose stimulation of the pancreatic b-cell, but not the a-cell , Wang et al. 2008 . In contrast, insulin stimulates PANDER secretion from the pancreatic a-TC1-6 cell line and appears to be located in an intracellular compartment distinct from glucagon . Palmitic acid has also been reported to induce PANDER mRNA and protein expression in a dose and time dependent manner in a pancreatic b-cell line (Chen et al. 2011 , Xiang et al. 2012 . In addition, the critical pancreatic b-cell-specific transcriptional factor, pancreatic-duodenal homeobox domain-1 (PDX1), interacts and increases the expression of the PANDER promoter (Burkhardt et al. 2008 ).
PANDER's location and regulation have led to a potential relationship with glucose regulation, and several animal models have been derived to study this with some conflicting results. Wilson et al. (2010) evaluated hepatic PANDER overexpression achieved through adenoviral delivery. This model revealed fasting hyperglycemia, hyperinsulinemia, and elevated corticosterone levels. Li et al. (2011) derived a similar adenoviral-delivered overexpressing model with different results, and did not observe glucose intolerance, fasting glycemia, or elevated corticosterone levels. However, liver and serum triglyceride content was increased along with serum insulin levels, as compared with WT mice. Differences between the studies may certainly be attributed to alterations in time and dose of adenoviral delivery and subsequent PANDER expression. Although prior animal models of PANDER have certainly revealed useful information, none provided a physiologically selective model of PANDER expression to focus on its function in the context of the observed in vivo tissue distribution of PANDER.
Therefore, to further elucidate the physiologic role of pancreas-secreted PANDER in vivo, our laboratory has created and phenotyped the only transgenic mouse model (PANDER transgenic, PANTG) with tissue-specific PANDER overexpression and secretion from the endocrine pancreas. Our metabolic phenotyping and proteomic analysis strongly indicate that endocrine-specific overexpression of PANDER impacts hepatic glycemic output and lipid regulation.
Materials and methods

Transgenic mouse generation and genotyping
The Fam3b (PANDER) gene cloned into the pCR2.1 cloning vector (Life Technologies) was kindly provided by GlaxoSmithKline. The Pander gene was excised and ligated downstream of the Pdx1 promoter which drives the expression exclusively in the endocrine tissue of the pancreas. This vector was obtained from Dr Maureen Gannon, Vanderbilt University (Samaras et al. 2002) . B6SJLF (strain generated from a cross between C57BL/6J females and SJL/J males) transgenic mice were produced according to the protocol of the University of Pennsylvania Transgenic and Chimeric Mouse Facility. During the course of this investigation, the laboratory and animal colony were moved to the University of South Florida (USF) from the Children's Hospital of Philadelphia. Frozen embryos of the PANTG were shipped to the Moffitt Stabile Vivarium on the campus of USF and implanted into pseudo pregnant females for subsequent rederivation of murine colony. Animals were fed standard chow from Purina and given water ad libitum. All animals were handled according to the guidelines established by the Institutional Animal Care and Use Committee at the University of South Florida and Children's Hospital of Philadelphia before relocation. Offspring were screened by PCR to confirm transgenic integration using primers specific (forward 5 0 -GCT GGA CAG GGG CAC GTC AGG AAT GAG CTC-3 0 and reverse 5 0 -TAC TCT GAG TCC AAA CCG GGC CCC TCT GCT-3 0 ) for the b-globin intron and PANDER transgene resulting in a 300 bp transgene-specific PCR product amplified from genomic DNA isolated from tail tissue (DNeasy Kit, Qiagen). All animals were born normally at the expected Mendelian frequency. Male mice aged 8 weeks to 8 months were evaluated in this study. Relative PANDER expression was determined by RT-PCR and western analysis as described previously (RobertCooperman et al. 2010) .
RT-PCR and western blot
Transgenic and WT mouse pancreatic islets were isolated by collagenase digestion followed by a Ficoll gradient, as described previously . Islet lysate was then evaluated for PANDER expression via RT-PCR and western analysis, as described previously . Western blotting analysis for hepatic insulin signaling molecules was carried out by initially isolating protein from snap-frozen livers, using the tissue protein extraction reagent (TPER; Thermo Fisher Scientific, Rockford, IL, USA). Hepatic lysate (typically 20-40 mg) was analyzed by SDS-PAGE (Bio-Rad Pre-Cast 12% TGX gels, Bio-Rad) and subsequently transferred onto PVDF membrane using the iBlot semi-dry transfer system (Invitrogen). Western blots were detected with antibodies for phosphorylated and total proteins of AMPK and acetyl coenzyme A carboxylase-1 (ACC; Cell Signaling, Danvers, MA, USA) diluted at 1:1000 in commercial StartBlock blocking buffer (Thermo Fisher Scientific). Detection was performed using peroxidase-conjugated secondary antibodies at 1:10 000 using chemiluminescence detection reagents and signals were visualized using the LAS 3000 Intelligent Dark Box (Fujifilm, Stamford, CT, USA). Protein levels were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Cell Signaling). Densitometry analysis was performed using Image J (version 1.45) analysis.
Immunohistochemistry of transgenic islets
Pancreatic sections from PANTG and WT mice were fixed for 24 h in formalin and embedded in paraffin as performed by Children's Hospital of Philadelphia pathology core. The sections were stained using aldehyde fuchsin or hematoxylin and eosin (H&E) stains. Immunostaining for insulin was performed with a guinea pig anti-insulin primary antibody (Dako, Carpinteria, CA, USA) and anti-guinea pig cy3 conjugated secondary antibody. Glucagon staining was done with a rabbit antiglucagon primary antibody (Dako) and anti-rabbit cy2 conjugated secondary antibody. PANDER staining was performed using a rabbit polyclonal PANDER antibody as described previously, followed by an anti-rabbit biotinylated secondary antibody which complexes with HRP-conjugated streptavidin molecules in a subsequent wash (Cao et al. 2003) .
PANDER ELISA
To measure the levels of PANDER in the serum, a commercial ELISA (Life Sciences Advanced Technologies, Cat No. E03P0025, St Petersburg, FL, USA) was carried out on the blood sample collected from the tail vein of PANTG and WT mice during fasted (16 h overnight) and fed (4 h exposure to food following overnight fast) conditions, according to manufacturer's instructions.
Animal growth measurement
WT and PANTG mice at 3-4 months of age were weighed (Beckman Digital Scale) in the morning upon overnight fasting and again at 5-6 months of age before stimulation testing. Weight in grams was averaged for each group and compared at the two designated time points (nZ40).
Glucose tolerance testing
Mice were fasted overnight (16 h) in a cage with fresh bedding before glucose tolerance testing (GTT). Blood glucose (BG) was measured immediately before glucose injection and then at 15, 30, 60, 90 and 120 min following i.p. injection of glucose at a concentration of 2 g/kg body weight. Blood was collected via tail vein and concentration of glucose was measured using a True Track Smart System glucometer (Home Diagnostics, Inc., Fort Lauderdale, FL, USA).
Insulin tolerance testing
Mice were fasted for 4 h in a cage with fresh bedding before insulin tolerance testing (ITT). BG levels were measured immediately before i.p. injection of insulin at a concentration of 1 U/kg of body weight. BG was then measured as above at 0, 15, 30, 60, 90 and 120 min post injection.
Hyperinsulinemic-euglycemic clamp
Clamp studies were performed by the University of Pennsylvania Mouse Phenotyping Core as described previously . For calculation, rates of whole-body glucose appearance and uptake were determined as the ratio of the H 3 glucose infusion rate (GIR) (disintegrations per min/min) to the specific activity of plasma glucose (dpm/mmol) during the final 30 min of clamps. Hepatic glucose production (HGP) during the hyperinsulinemic-euglycemic clamps (HEC) was determined by subtracting the GIR from the wholebody glucose appearance.
Serum collection for hormones and triglyceride assays
Mice were fasted for 16 h before serum collection. Blood was obtained by vein puncture and free flow collection in SarStead collection tubes. The whole blood samples were centrifuged for 5 min and the serum was separated to a new collection tube. The hormone analytes were measured using Luminex Multiplex Platform (MAGPIX), with commercial mouse endocrine panel (Millipore Kit MMHMAG-44K; EMD Millipore, Billerica, MA, USA), ENZO EIA assay kit for corticosterone, and Abcam Triglyceride Kit.
Stable isotope labeling of amino acids to cell culture
Isolated liver lysate was prepared from PANTG and WT male mice (nZ6 per group) during random fed conditions. Livers were homogenized in TPER buffer (Thermo Fisher Scientific) followed by high-speed centrifugation. Ethanol-treated AML-12 cells were utilized as a surrogate cell line for comparing protein, as described previously (Monetti et al. 2011) . The AML-12 cells were heavy labeled by culturing in a medium containing 13 C 6 L-lysine-2-HCl and 13 C 6 L-arginine-HCl followed by homogenization in MPER buffer (Thermo Fisher Scientific, Rockford, IL, USA) followed by high-speed centrifugation. Supernatants were collected and protein concentration was quantified (Pierce BCA protein assay). Equivalent amount of liver protein was then spiked with equal mass of protein from AML-12s. The spiked mixture was solubilized using FASP protein digestion kit (Protein Discovery, Knoxville, TN, USA). The six samples derived from PANTG and WT livers, respectively, were then batched and both samples were desalted before fractionation using an automated CXS column. Nine fractions were selected for both PANTG and WT mice and subsequently dissolved in 1% aqueous formic acid for evaluation by mass spectrometry (LTQ Orbitrap XL TM Hybrid Ion Trap-Orbitrap Mass Spectrometer; Thermo Fisher Scientific). Data were normalized and analyzed using the Ingenuity Pathway Analysis (IPA) program. A total of 1640 proteins were confidently identified and quantitated.
Relative changes in the levels of identified proteins were determined by the ratio of PANTG to that of WT and normalized to Tubulin B5. Of those, 88 protein groups were upregulated and nine were downregulated (P!0.05 for both groups). The distribution of ratios of all quantitated proteins indicated excellent representation of the proteome between PANTG and WT ratio relative to that of AML-12 cells
Statistical analysis
Statistical analysis of the data was performed using GraphPad Prism software (La Jolla, CA, USA). Data are shown as meanGS.E.M. Statistical significance of differences between groups was analyzed by unpaired Student's t-test. A P value of !0.05 was considered significant.
Results
Endocrine pancreas-specific PANDER overexpression in the PANTG
A 1 kb fragment of the PDX1 promoter was used to drive PANDER overexpression specifically in the endocrine tissue of the pancreas (Fig. 1A ). This region of PDX1 has been extensively characterized and demonstrated to govern endocrine-specific expression (Melloul et al. 2002) . The construct also contains an Hsp68 cassette that functions as a basal promoter, as the Pdx1 promoter lacks a TATA box. A b-globin intron fragment and polyA cassette flanking PANDER was incorporated to promote RNA stability ( analysis demonstrated an approximate eight-to tenfold increase in Pander expression in pancreatic islets from 2-month-old PANTG as compared with WT mice. As expected, the mature (26 kDa) and secreted (23 kDa) forms of the PANDER protein were both increased in the PANTG pancreatic islets (Fig. 1C ). Increased Pander expression from the PANTG islets was also observed in older mice aged 5-7 months (data not shown). Due to detection limitations of our current antibody, the precise amount of circulating serum PANDER is unknown. Islets isolated from the PANTG secrete significantly higher quantities of PANDER upon glucose stimulation than WT islets . However, we also wanted to confirm that increased PANDER levels were only found within the endocrine pancreas. Immunohistochemical analysis of pancreatic sections from PANTG and WT mice revealed increased Pander expression specifically to the endocrine pancreas and not to the surrounding exocrine tissue (Fig. 1D ). Due to previous data indicating that PANDER can induce apoptosis in pancreatic b-cell (Cao et al. 2003 (Cao et al. , 2005 , morphological differences between PANTG and WT pancreatic islets were evaluated. These differences included islet size, changes in secretory granules or localization of insulin and glucagon. Therefore, pancreatic islets were assessed using immunohistochemistry for various morphological changes. Staining with hematoxalin and eosin and aldehyde fuchsin showed normal islet and pancreatic morphology with no lymphocytic infiltrate in PANTG mice ( Fig. 1E and F) . The islets were comparable in size and shape upon microscopic evaluation. Insulin distribution in PANTG mice when visualized with aldehyde fuchsin staining was similar with that in WT mice. Localization of insulin and glucagon within islets was comparable between PANTG and WT mice as visualized with immunofluorescence (Fig. 1G) . Insulin-expressing cells were located throughout the islet core with glucagon-expressing cells mainly within the mantle or periphery. Hence, at the microscopic level, islet morphology in PANTG mice was similar to WT with PANDER overexpression localized to the endocrine pancreas.
To measure PANDER levels in the blood, serum was collected from fasting and fed PANTG and WT mice and evaluated by a recently developed commercial ELISA for the detection of murine PANDER (Life Sciences Advanced Technologies). In general, circulating PANDER in both the fasted and fed states was approximately fourfold higher in the PANTG as compared with matched WT serum (Fig. 1H) . Another critical tissue with regard to PANDER expression has been the liver. Therefore, hepatic PANDER levels were examined by western analysis and did not reveal a significant difference between both groups ( Fig. 1I and J) . However, it should be noted that a non-statistical trend of increased PANDER levels was observed in the PANTG as compared with the WT during fed conditions (Fig. 1J) .
Increased fasting glucose and insulin levels in the PANTG mouse
To initially characterize the impact of overexpressed endocrine-specific PANDER on glycemia, glucose levels were measured in PANTG mice following an overnight fast. PANTG mice revealed a significantly elevated BG at 2 months of age compared with WT littermates, with values of 238 mg/dlG29 vs 153 mg/dlG8, respectively, with P!0.05 as seen in Fig. 2A . The difference in fasting glycemia was diminished over time due to WT group (6 months of age) having increased glucose levels potentially attributed to age-dependent insulin resistance ( Fig. 2A) . Significantly higher (P!0.001) glycemic values were measured from the PANTG when measuring across both age groups (PANTG 233.8G18.6 vs WT 178.1G8.8, P!0.001). To further uncover potential mechanisms of the observed fasting hyperglycemia, we measured the levels of the various hormones of insulin, C-peptide, glucagon, leptin, and resistin. PANTG displayed a significant elevation in insulin compared with WT; 619.3 pg/mlG165.6. vs 179.6 pg/mlG94.4, respectively (P! 0.05) along with C-peptide levels compared with WT; 1629 pg/mlG394 vs 493 pg/mlG246, respectively (P!0.05) (Fig. 2B) . No significant differences were observed for glucagon, resistin, or leptin. In addition, corticosterone values were also measured and found to be similar with that of WT mice (data not shown). In summary, the initial phenotyping of the PANTG demonstrated increased fasting glycemic and insulinemic levels in the absence of increased glucagon or corticosterone.
Glucose intolerance in PANTG
To evaluate the role of PANDER during fed conditions, PANTG mice were examined during fed or insulinstimulated conditions. GTT's demonstrated higher BG levels at completion of the 2 h timed test in PANTG vs WT male mice aged 3 months (P!0.05) (Fig. 3A) . However, the % glycemic change from baseline was not significantly different between both groups at the conclusion of the GTT (PANTG 156G18% vs WT 155G24.7%, not significant, data not shown). Differences in glucose intolerance diminished over time as indicated by GTT performed on 6-month-old mice, but both groups showed elevated glucose levels during the course of GTT as compared with the younger cohort (Fig. 3B) . To evaluate peripheral insulin sensitivity, ITTs were performed. ITT results demonstrated similar peripheral insulin sensitivity for the PANTG and WT mice in both age groups ( Fig. 3C and D). In general, PANTG mice demonstrated temporaldependent glucose intolerance without the presence of peripheral insulin resistance.
Hepatic insulin resistance in PANTG
To further investigate the potential mechanism for the observed fasting hyperglycemia and glucose intolerance, HEC studies were performed to further evaluate insulin sensitivity. GIR and rate of glucose disappearance (Rd) were similar for both PANTG and WT mice and indicated no significant differences in peripheral insulin sensitivity based on the GIR (Fig. 4A) and Rd (Fig. 4B) . However, differences were observed with regard to the evaluation of hepatic insulin sensitivity. During the HEC, PANTG mice demonstrated a lower percent suppression and higher HGP as compared with WT mice (P!0.05) ( Fig. 4C and D) . Taken together, these results indicate that pancreasspecific overexpressed PANDER can decrease hepatic insulin sensitivity but not peripherally and alludes to a liver-specific role of PANDER.
Hepatic SILAC analysis of PANTG demonstrates increased gluconeogenic and lipogenic predicted networks
Our initial characterization of the PANTG revealed increased fasting and post-prandial glycemic levels in the absence of peripheral insulin resistance but in the presence of hepatic insulin resistance. Therefore, we then investigated critical hepatic insulin signaling molecules via a comprehensive proteomic approach known as stable isotope labeling of amino acids in cell culture (SILAC). This quantitative proteomic strategy metabolically labels the entire proteome and allows for identification and network elucidation by mass spectrometry analysis and has become a highly useful and relatively novel tool to identify complex protein mixtures, signaling cascades, and regulated protein modifications (Kruger et al. 2008 , Monetti et al. 2011 . Total protein isolate was prepared from extracted livers from PANTG and WT mice (nZ6 per group) obtained during fed conditions. Following processing and SILAC analysis, w1640 proteins were identified and quantitated. Data were normalized and analyzed using the IPA program. Relative changes in the levels of identified proteins were determined by the ratio of PANTG to that of WT and normalized to proteomic expression of Tubulin B5. Of those, 88 protein groups were upregulated and nine were downregulated (P!0.05 for both groups). IPA of the differentially expressed proteins identified lipid metabolism as one of the top associated network functions as significantly upregulated (20 total proteins with PZ9.46! 10 K6 ) with an overall score of 57 (score of 2 is significant) (Fig. 5A) . Further IPA analysis identified quantity of triacylglycerol that is predicted to be in an increased state (z-score of 2.4) with a genetic network of interacting proteins consisting of fatty acid binding protein (FABP1), protein kinase A type II-b regulatory subunit (PRKAR2B), phosphoenol-pyruvate carboxykinase (PEPCK), sterol carrier protein (SCP2), acetyl CoA synthetase (ACSL1), and ectonucleoside triphosphate diphosphohydrolase 5 (ENTPD5) (Fig. 5B and C) . Of those identified to promote increased triglyceride production, four revealed to molecularly interact as determined by IPA (Fig. 5C ). Overall, SILAC identified a proteomic profile within the PANTG liver of increased lipid metabolism and increased PEPCK (gluconeogenic) expression, supporting the observed results obtained with both the HEC and SILAC analysis.
PANTG mice display elevations in liver triglyceride content
HEC and SILAC results of the PANTG strongly suggested an impact in hepatic signaling pathways, with potential alterations in triglyceride content and potential signaling molecules. Therefore, we measured hepatic triglyceride and glycogen content. Hepatic triglycerides were elevated, while glycogen content was significantly decreased in the livers of the PANTG mice as compared with WT ( Fig. 6A and B, P!0.05). Significant differences in body weight were not observed between PANTG and WT mice at either age (Fig. 6C) . With the observed pleiotropic PANDERinduced effects on hepatic triglyceride, glycogen and hepatic insulin signaling, we evaluated the potential of PANDER altering the expression of AMPK and it's downstream target of ACC. Western blot analysis of PANTG livers examined in the fasted and insulin-stimulated conditions revealed an overall trend of decreased phosphorylation of p-AMPK and corresponding p-ACC ( Fig. 6D and E). However, statistical significance was only observed during fasting conditions of decreased p-ACC and insulinstimulated conditions for p-AMPK of the PANTG (Fig. 6F , G, H, and I). Therefore, overexpression of PANDER from the pancreatic b-cell decreases hepatic p-AMPK signaling and to a limited extent provides a potential mechanism for the observed increased lipogenesis and gluconeogenesis within this model. 
Discussion
The hallmark characteristics of our PANTG model in younger male mice demonstrated the following: 1) increased fasting hyperglycemia and insulinemia, 2) impaired glucose tolerance, 3) increased hepatic insulin resistance, 4) increased proteomic profile of lipogenesis and gluconeogenesis, 5) increased hepatic triglyceride content, 6) decreased hepatic glycogen, and 7) decreased p-AMPK signaling. These findings strongly suggest that pancreas-specific PANDER can alter glycemic levels through what appears to be a specific interaction with the liver and impact phosphorylation of critical downstream hepatic signaling molecules such as AMPK. The generation and evaluation of the pancreas-specific PAN-DER overexpressing transgenic mouse allowed us to evaluate the physiologic effects of secreted PANDER and the impact on glycemic and lipid modulation.
To put our data in the context of other published in-vivo studies, we compared our results to the overall findings of others, albeit this comparison was made to acute models (Table 1 ). The two other published studies utilized tail vein-injected adenoviral-delivered PANDER to induce a hepatic overexpression of PANDER . Some of the earliest reports detailing the localization of PANDER did not find any expression in the liver (Zhu et al. 2002) , but recently others have surfaced to demonstrate that PANDER is expressed within this organ as well and is consistent with our findings . Therefore, there is definitive physiological relevance to this approach but does not take into account the biological influence of pancreas-specific PANDER. Both prior studies evaluated the impact of Ad-PANDER following either 3 administration. There were numerous differences in phenotypic observations between these prior studies that included fasting glycemia, corticosterone levels, glucose tolerance, hepatic triglycerides, and intracellular hepatic signaling such as with AMPK. Our findings appeared to strongly complement the overall but sometimes contrasting data presented from both studies in that observations that were identified in a single acute study were also identified with the PANTG (Table 1) . Taken together, this may indicate overlapping roles between hepatic and pancreatic-specific PANDER that may complement each other and provide a synergistic effect on glycemic levels and hepatic insulin sensitivity. In combination with the findings from the Pander knockout mouse, PANDER may serve distinct biological roles in the regulation of glycemic levels. The previously reported PANKO mouse displayed impaired insulin secretion and glucose tolerance due to abnormal calcium signaling within the pancreatic islets.
However, this model also demonstrated enhanced hepatic insulin signaling along with decreased HGP during HEC studies. The previous knockout results in addition to our currently presented transgenic study allude to the pleiotropic nature of this novel class of hormones with regard to biological action within pancreatic b-cell and hepatic metabolic pathways. Furthermore, PANDER may even serve a function in cell survival as there is extensive literature supporting that PANDER has a pro-apoptotic effect on pancreatic islets in vitro (Cao et al. 2003 . However, this study did not reveal any increased pancreatic islet apoptosis by 5-bromo-2-deoxyuridine staining (data not shown). This discrepancy between experimental observations may be attributed to compensatory mechanisms present in vivo that may promote cell survival or the levels of PANDER overexpression within this model are not sufficiently high enough to induce apoptosis. A distinguishing trait among all PANDER models is the increase in fasting hyperinsulinemia as compared with WT controls (Table 1) . This observation may be the result of either increased pancreatic b-cell secretion, impaired insulin sensitivity, or compensatory consequence of increased fasting glycemia. Data from others and investigations from our laboratory (data not shown) certainly indicate impaired hepatic insulin sensitivity with mild to no impact of PANDER overexpression on pancreatic b-cell secretion insulin secretion. In contrast, the Pander knockout on mixed genetic background has demonstrated impaired insulin secretion with decreased glucosestimulated intracellular calcium signaling, providing evidence of a pleiotropic role of PANDER in islets as well as liver . However, in the context of our transgenic and the acute models, the increased fasting hyperinsulinemia appears to be attributed to decreased hepatic but not peripheral insulin sensitivity. Our HEC studies have provided some of the strongest data supporting this conclusion and exhibited no significant differences in GIR and rate of disappearance but increased HGP (Fig. 4C) . This elevated HGP can also be the result of increased circulating hormones such as glucagon or corticosterones that can enhance cAMP and CREB signaling (Dirlewanger et al. 2000 , Jiang & Zhang 2003 . However, our study did not demonstrate any altered levels in corticosteroids or glucagon and indicate that the elevated HGP is attributed to hepatic insulin resistance along with the selective PANDER-induced effects.
Type 2 diabetes (T2D) is characterized by insulin resistance in a multitude of tissues, resulting in a compensatory or consequential physiological condition of the typical T2D metabolic triad of hyperinsulinemia, hyperglycemia, and hypertriglyceridemia (Muoio & Newgard 2008) . Hepatic insulin resistance is a major component of T2D, resulting in decreased suppression of HGP due to blunted insulin signaling (Saad et al. 1992 , Kerouz et al. 1997 . However, there is a major uncharacterized detrimental paradox with hepatic insulin resistance in T2D that has yet to be elucidated in that it is selective rather than total (Brown & Goldstein 2008) . Despite impaired insulin signaling, hepatic lipogenesis is increased resulting in excessive production of fatty acid synthesis and triglyceride accumulation, resulting in a highly detrimental condition and promotion of metabolic syndrome and further insulin resistance. Total insulin resistance in the liver-specific insulin receptor knockout (LIRKO) mouse demonstrated that insulin fails to decrease gluconeogenesis and synthesis of fatty acids, indicating that this is a less severe metabolic defect than selective hepatic insulin resistance (SHIR; Biddinger et al. 2008 ). The precise mechanism and cofactors responsible for the onset and progression of SHIR are unknown. Taken together, the PANTG demonstrates a SHIR-like phenotype due to simultaneous presence of hepatic insulin resistance with increased HGP and lipogenesis. HEC and SILAC results together provide the evidence of increased HGP and PEPCK expression with a stimulation of triglyceride production and provide potentially novel pathways for the onset of SHIR. One potential conclusion is that PANDER may serve as a cofactor in the onset of SHIR in T2D. Experiments evaluating the secretagogues of PANDER strongly implicate that hallmark T2D conditions of hyper-glycemia, insulinemia, and lipidemia would promote PANDER expression , Wang et al. 2008 . Three recent reviews have arrived at similar conclusions implicating PANDER in the onset and progression of hepatic insulin resistance in T2D and potentially nonalcoholic fatty liver disease (Wilson et al. 2011 , Wang et al. 2012 , Yang & Guan 2013 . Further extensive studies evaluating subjects with and without T2D in context of PANDER levels are needed to fully warrant this conclusion.
Proteomics by SILAC analysis revealed upregulation of a network of key genes related to gluconeogenesis and lipogenesis, specifically PEPCK, FABP1, PRKAR2B, SCP2, ACSL1, and ENTPD5. PEPCK controls the rate limiting step in gluconeogenesis and suppression is expected under conditions of hyperglycemia and insulin secretion (Hanson & Reshef 1997) . ACSL1 is an isozyme of the longchain fatty-acid-coenzyme A ligase family that convert Wilson et al. (2010) and Li et al. (2011), respectively. PANTG describes summary of results from currently described study free long-chain fatty acids into fatty acyl-CoA esters, and serve a central role in lipid biosynthesis (Ning et al. 2011) . Proteins of FABP1 and SCP2 serve as binding and carrier proteins involved in lipid homeostasis (Amigo et al. 2003 , Newberry et al. 2003 , PRKAR2B and ENTPD5 are involved in the substrate production necessary for lipogenesis (Schreyer et al. 2001 , Read et al. 2009 ). In addition, AMPK is known to have numerous effects upon hepatic metabolism, including inhibition of gluconeogenesis, lipogenesis, and glycogen production (Canto & Auwerx 2010) . In particular, activation of AMPK decreases hepatic triglyceride production by increasing b oxidation in the cell (Winder & Hardie 1999) . Concordantly, we observed decreased p-AMPK upon insulin stimulation with an observed increase in glycogen production and hepatic triglycerides. During pathological conditions, PANDER may promote SHIR by disrupting activation and phosphorylation of p-AMPK. AMPK inhibits ACC, an enzyme responsible for the synthesis of malonyl-CoA that results in increased triglyceride synthesis. Our results in the PANTG are consistent with decreased p-AMPK and p-ACC resulting in increased hepatic triglyceride production. Further studies are needed and ongoing to elucidate the PANDER receptor and additional signaling molecules impacted by PANDERinduced inhibition of p-AMPK.
In summary, the generation and characterization of the PANTG reveals that pancreas-secreted PANDER serves a selective role in the counter-regulation of hepatic insulin action by impairing insulin-induced suppression of gluconeogenesis but by promoting hepatic triglyceride production under typical physiological conditions. However, under pathological conditions such as in T2D, PANDER may impart SHIR and serve as a co-factor driving a detrimental cycle of hepatic insulin resistance.
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